Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.
Cimetidine, a new H2-receptor antagonist, was safely administered to eighteen healthy man by the intravenous, intraduodenal or oral route. 2 When gastric secretion was maximally stimulated by either histamine or pentagastrin, the simultaneous administration of cimetidine produced marked inhibition of both acid and pepsin secretion. 3 Cimetidine was well absorbed by mouth and had a blood half-life of 2 hours. 4 Cimetidine was rapidly excreted via the kidneys and about 70% of the excreted material was unchanged drug. 5 Clinical evaluation of cimetidine in patients with peptic ulceration is recommended.
D000284:Administration, Oral; D000328:Adult; D004386:Duodenum; D005750:Gastric Juice / Q000378:metabolism; D006146:Guanidines / Q000494:pharmacology*; D006207:Half-Life; D006632:Histamine / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D007263:Infusions, Parenteral; D007441:Intubation, Gastrointestinal; D008297:Male; D008875:Middle Aged; D010418:Pentagastrin / Q000494:pharmacology; D010434:Pepsin A / Q000378:metabolism
D006146:Guanidines; D006635:Histamine H2 Antagonists; D007093:Imidazoles; D006632:Histamine; D010434:Pepsin A; D010418:Pentagastrin